Last reviewed · How we verify
Kidney transplant maintenance immunosuppression
Kidney transplant maintenance immunosuppression regimens suppress the recipient's immune system to prevent rejection of the transplanted organ.
Kidney transplant maintenance immunosuppression regimens suppress the recipient's immune system to prevent rejection of the transplanted organ. Used for Kidney transplant maintenance immunosuppression to prevent allograft rejection.
At a glance
| Generic name | Kidney transplant maintenance immunosuppression |
|---|---|
| Also known as | Advagraf |
| Sponsor | Imperial College Healthcare NHS Trust |
| Drug class | Immunosuppressive combination therapy |
| Modality | Small molecule |
| Therapeutic area | Immunology / Transplantation |
| Phase | FDA-approved |
Mechanism of action
These regimens typically combine multiple immunosuppressive agents (such as calcineurin inhibitors, antiproliferatives, and corticosteroids) that work synergistically to inhibit T-cell activation and proliferation, reducing the immune response against the foreign transplanted kidney. The goal is to achieve sufficient immunosuppression to prevent acute and chronic rejection while minimizing drug toxicity and infection risk.
Approved indications
- Kidney transplant maintenance immunosuppression to prevent allograft rejection
Common side effects
- Infection (bacterial, viral, fungal)
- Nephrotoxicity
- Hypertension
- Hyperglycemia / new-onset diabetes
- Hyperlipidemia
- Bone disease / osteoporosis
- Malignancy
- Tremor
- Gingival hyperplasia
Key clinical trials
- Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients (PHASE2)
- Reduced Immunosuppression in Older Renal Transplant Recipients With Trugraf®/TRAC Monitoring (RIOT Trial): A Prospective, Randomized, Multicenter Trial. (PHASE4)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- Valganciclovir Prophylaxis Versus Preemptive Therapy for Cytomegalovirus in Living Donor Kidney Transplant Recipients (PHASE4)
- Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies (PHASE1, PHASE2)
- Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant (PHASE4)
- Eculizumab Therapy for Subclinical Antibody-mediated Rejection in Kidney Transplantation (PHASE1, PHASE2)
- Eduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and/or Acute Respiratory Failure (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: